335 related articles for article (PubMed ID: 25319391)
1. Targeting JAK1/STAT3 signaling suppresses tumor progression and metastasis in a peritoneal model of human ovarian cancer.
Wen W; Liang W; Wu J; Kowolik CM; Buettner R; Scuto A; Hsieh MY; Hong H; Brown CE; Forman SJ; Horne D; Morgan R; Wakabayashi M; Dellinger TH; Han ES; Yim JH; Jove R
Mol Cancer Ther; 2014 Dec; 13(12):3037-48. PubMed ID: 25319391
[TBL] [Abstract][Full Text] [Related]
2. Cytokine receptor signaling is required for the survival of ALK- anaplastic large cell lymphoma, even in the presence of JAK1/STAT3 mutations.
Chen J; Zhang Y; Petrus MN; Xiao W; Nicolae A; Raffeld M; Pittaluga S; Bamford RN; Nakagawa M; Ouyang ST; Epstein AL; Kadin ME; Del Mistro A; Woessner R; Jaffe ES; Waldmann TA
Proc Natl Acad Sci U S A; 2017 Apr; 114(15):3975-3980. PubMed ID: 28356514
[TBL] [Abstract][Full Text] [Related]
3. Targeted Blockade of JAK/STAT3 Signaling Inhibits Ovarian Carcinoma Growth.
Gritsina G; Xiao F; O'Brien SW; Gabbasov R; Maglaty MA; Xu RH; Thapa RJ; Zhou Y; Nicolas E; Litwin S; Balachandran S; Sigal LJ; Huszar D; Connolly DC
Mol Cancer Ther; 2015 Apr; 14(4):1035-47. PubMed ID: 25646015
[TBL] [Abstract][Full Text] [Related]
4. Synergistic anti-tumor effect of combined inhibition of EGFR and JAK/STAT3 pathways in human ovarian cancer.
Wen W; Wu J; Liu L; Tian Y; Buettner R; Hsieh MY; Horne D; Dellinger TH; Han ES; Jove R; Yim JH
Mol Cancer; 2015 May; 14():100. PubMed ID: 25928246
[TBL] [Abstract][Full Text] [Related]
5. Elevated STAT3 expression in ovarian cancer ascites promotes invasion and metastasis: a potential therapeutic target.
Saini U; Naidu S; ElNaggar AC; Bid HK; Wallbillich JJ; Bixel K; Bolyard C; Suarez AA; Kaur B; Kuppusamy P; Hays J; Goodfellow PJ; Cohn DE; Selvendiran K
Oncogene; 2017 Jan; 36(2):168-181. PubMed ID: 27292260
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of the JAK2/STAT3 pathway in ovarian cancer results in the loss of cancer stem cell-like characteristics and a reduced tumor burden.
Abubaker K; Luwor RB; Zhu H; McNally O; Quinn MA; Burns CJ; Thompson EW; Findlay JK; Ahmed N
BMC Cancer; 2014 May; 14():317. PubMed ID: 24886434
[TBL] [Abstract][Full Text] [Related]
7. Nitidine chloride inhibits hepatocellular carcinoma cell growth in vivo through the suppression of the JAK1/STAT3 signaling pathway.
Liao J; Xu T; Zheng JX; Lin JM; Cai QY; Yu DB; Peng J
Int J Mol Med; 2013 Jul; 32(1):79-84. PubMed ID: 23613111
[TBL] [Abstract][Full Text] [Related]
8. Activation of IL-6R/JAK1/STAT3 signaling induces de novo resistance to irreversible EGFR inhibitors in non-small cell lung cancer with T790M resistance mutation.
Kim SM; Kwon OJ; Hong YK; Kim JH; Solca F; Ha SJ; Soo RA; Christensen JG; Lee JH; Cho BC
Mol Cancer Ther; 2012 Oct; 11(10):2254-64. PubMed ID: 22891040
[TBL] [Abstract][Full Text] [Related]
9. Targeting EphA2 suppresses hepatocellular carcinoma initiation and progression by dual inhibition of JAK1/STAT3 and AKT signaling.
Wang H; Hou W; Perera A; Bettler C; Beach JR; Ding X; Li J; Denning MF; Dhanarajan A; Cotler SJ; Joyce C; Yin J; Ahmed F; Roberts LR; Qiu W
Cell Rep; 2021 Feb; 34(8):108765. PubMed ID: 33626345
[TBL] [Abstract][Full Text] [Related]
10. JAK1/STAT3 Activation through a Proinflammatory Cytokine Pathway Leads to Resistance to Molecularly Targeted Therapy in Non-Small Cell Lung Cancer.
Shien K; Papadimitrakopoulou VA; Ruder D; Behrens C; Shen L; Kalhor N; Song J; Lee JJ; Wang J; Tang X; Herbst RS; Toyooka S; Girard L; Minna JD; Kurie JM; Wistuba II; Izzo JG
Mol Cancer Ther; 2017 Oct; 16(10):2234-2245. PubMed ID: 28729401
[TBL] [Abstract][Full Text] [Related]
11. Leukemia inhibitory factor functions in parallel with interleukin-6 to promote ovarian cancer growth.
McLean K; Tan L; Bolland DE; Coffman LG; Peterson LF; Talpaz M; Neamati N; Buckanovich RJ
Oncogene; 2019 Feb; 38(9):1576-1584. PubMed ID: 30305729
[TBL] [Abstract][Full Text] [Related]
12. JAK kinase inhibition abrogates STAT3 activation and head and neck squamous cell carcinoma tumor growth.
Sen M; Pollock NI; Black J; DeGrave KA; Wheeler S; Freilino ML; Joyce S; Lui VW; Zeng Y; Chiosea SI; Grandis JR
Neoplasia; 2015 Mar; 17(3):256-64. PubMed ID: 25810010
[TBL] [Abstract][Full Text] [Related]
13. Inhibitory effects of STAT3 decoy oligodeoxynucleotides on human epithelial ovarian cancer cell growth in vivo.
Zhang X; Liu P; Zhang B; Mao H; Shen L; Ma Y
Int J Mol Med; 2013 Sep; 32(3):623-8. PubMed ID: 23828376
[TBL] [Abstract][Full Text] [Related]
14. Targeting an autocrine IL-6-SPINK1 signaling axis to suppress metastatic spread in ovarian clear cell carcinoma.
Mehner C; Miller E; Hockla A; Coban M; Weroha SJ; Radisky DC; Radisky ES
Oncogene; 2020 Oct; 39(42):6606-6618. PubMed ID: 32929152
[TBL] [Abstract][Full Text] [Related]
15. Inflammation-driven senescence-associated secretory phenotype in cancer-associated fibroblasts enhances peritoneal dissemination.
Yasuda T; Koiwa M; Yonemura A; Miyake K; Kariya R; Kubota S; Yokomizo-Nakano T; Yasuda-Yoshihara N; Uchihara T; Itoyama R; Bu L; Fu L; Arima K; Izumi D; Iwagami S; Eto K; Iwatsuki M; Baba Y; Yoshida N; Ohguchi H; Okada S; Matsusaki K; Sashida G; Takahashi A; Tan P; Baba H; Ishimoto T
Cell Rep; 2021 Feb; 34(8):108779. PubMed ID: 33626356
[TBL] [Abstract][Full Text] [Related]
16. Emodin inhibits growth and induces apoptosis in an orthotopic hepatocellular carcinoma model by blocking activation of STAT3.
Subramaniam A; Shanmugam MK; Ong TH; Li F; Perumal E; Chen L; Vali S; Abbasi T; Kapoor S; Ahn KS; Kumar AP; Hui KM; Sethi G
Br J Pharmacol; 2013 Oct; 170(4):807-21. PubMed ID: 23848338
[TBL] [Abstract][Full Text] [Related]
17. Berberine suppresses bladder cancer cell proliferation by inhibiting JAK1-STAT3 signaling via upregulation of miR-17-5p.
Xia Y; Chen S; Cui J; Wang Y; Liu X; Shen Y; Gong L; Jiang X; Wang W; Zhu Y; Sun S; Li J; Zou Y; Shi B
Biochem Pharmacol; 2021 Jun; 188():114575. PubMed ID: 33887260
[TBL] [Abstract][Full Text] [Related]
18. Hyperactive EGF receptor, Jaks and Stat3 signaling promote enhanced colony-forming ability, motility and migration of cisplatin-resistant ovarian cancer cells.
Yue P; Zhang X; Paladino D; Sengupta B; Ahmad S; Holloway RW; Ingersoll SB; Turkson J
Oncogene; 2012 May; 31(18):2309-22. PubMed ID: 21909139
[TBL] [Abstract][Full Text] [Related]
19. Novel hybrid molecule overcomes the limited response of solid tumours to HDAC inhibitors via suppressing JAK1-STAT3-BCL2 signalling.
Huang Z; Zhou W; Li Y; Cao M; Wang T; Ma Y; Guo Q; Wang X; Zhang C; Zhang C; Shen W; Liu Y; Chen Y; Zheng J; Yang S; Fan Y; Xiang R
Theranostics; 2018; 8(18):4995-5011. PubMed ID: 30429882
[TBL] [Abstract][Full Text] [Related]
20. Abrogation of constitutive Stat3 activity circumvents cisplatin resistant ovarian cancer.
Ji T; Gong D; Han Z; Wei X; Yan Y; Ye F; Ding W; Wang J; Xia X; Li F; Hu W; Lu Y; Wang S; Zhou J; Ma D; Gao Q
Cancer Lett; 2013 Dec; 341(2):231-9. PubMed ID: 23962558
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
